Mink Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Mink Therapeutics Inc Reports Q1 Loss Per Share Of $0.17
Mink Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: MiNK Therapeutics Announces Clinical Data Of Allogeneic Inkt Cells (Agent-797) In Solid Tumor Cancers
U.S. RESEARCH ROUNDUP-Adobe, Nike, Roper Technologies
Mink Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Mink Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
Mink Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Mink Therapeutics To Present Updated Clinical Data Of Allo-Inkt Cell Therapy In Solid Tumors At Aacr Annual Meeting
Brief: Mink Therapeutics Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Mink Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Mink Therapeutics Reports Quarterly Loss Per Share Of $0.19
Mink Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Mink Therapeutics Posts Q2 Loss Per Share $0.18
Brief: Mink Therapeutics Reports Q1 Loss Per Share Of $0.23
Brief: Mink Therapeutics Provides Corporate Update And Reports Fourth Quarter Results
Brief: MiNK Therapeutics Announces 77% Survival Rate In Intubated Patients With COVID-19 Respiratory Failure Treated With AgenT-797
Brief: Mink Therapeutics Inc Shares Open 0.3% Above IPO Price In Nasdaq Debut
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:59 AM